Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report

Table 1 Laboratory data before kidney biopsy

Blood examination		Urinary examination
ALB (g/L, 35–55)	18.3	RBC (cell/HPF, 0–4.5)	65.3
SCr (μmol/L, 35–106)	97.3	Proteinuria (g/24 h, < 0.16)	17.84
eGFR (mL/min/1.73 m2)	78.9	mALB/Cr (mg/mmoL Cr, < 3.7)	560.55
UA (μmol/L, 150–420)	465	α1-MG (mg/dL, < 1.25)	41.1
CHO (mmol/L, < 5.2)	7.68	β2-MG (μg/L, 0–150)	16573.54
TG (mmol/L, < 1.7)	3.64	IgG-lambda-M protein (neg.)	Positive
IgG-lambda-M protein (g/L, neg.)	0.9
FLC-lambda (mg/L, 5.71–26.3)	28.1	Hepatitis serology	-
FLC-kappa/lambda (0.26–1.65)	0.61	Anti-HBs (mIU/mL, < 10)	721
Anti-PLA2R (RU/mL, 4–20)	374.3	Anti-HBc (COI, > 1)	0.03
IgG (mg/dL, 694–1620)	357	HBV-DNA (IU/mL, < 100)	< 0.01
IgA (mg/dL, 68–378)	53.9	Anti-HCV (neg.)	Negative
C3, C4	Normal	HIV Ag/Ab (neg.)	Negative
RF (IU/mL, < 20)	20.2
Autoantibodies (ANA, MPO, ANCA, anti-SSA, anti-SSB)	Negative	Hematology	-
Coagulation	Normal	WBC (×109 cell/L, 3.5–9.5)	9.6
BNP, hsTnI	Normal	HB (g/L, 130–175)	123

ALB: Albumin; Anti-PLA2R: Phospholipase A2 receptor antibody; ANA: Antinuclear antibody, anti-SSA: Anti-Sjögren's-syndrome-related antigen A; Anti-HBs: Hepatitis B surface antibody; Anti-HBc: Hepatitis B core antibody, anti-HCV: Hepatitis C virus antibody; α1-MG: α1-microglobulin; BNP: B-type natriuretic peptides; β2-MG: β2-microglobulin; CHO: Cholesterol; C3: Complement 3; C4: Complement 4; eGFR: Estimated glomerular filtration rate; FLC: Free light-chain; hsTnI: High-sensitive troponin I; HIV Ag/Ab: Human immunodeficiency virus antigen/antibody; HBV: Hepatitis B virus; Hb: Hemoglobin; IgA: Immunoglobulin A; IgG: Immunoglobulin G; MPO-ANCA: Myeloperoxidase antineutrophil cytoplasmic antibody; RF: Rheumatoid factor; RBC: Red blood cell; SCr: Serum creatinine; TG: Triglyceride; UA: Uric acid; WBC: White blood cell.